Report from Annual General Meeting of XVIVO Perfusion AB (publ)

At XVIVO Perfusion’s Annual General Meeting today, April 23, the following,
amongst other things, was decided:

• No dividend will be paid for the financial year 2014.

• Re-election of Board members Semmy Rülf, Erik von Schenck, Magnus Nilsson,
Fredrik Mattsson, Folke Nilsson and Gösta Johannesson, in accordance with the
election committee’s proposal. Fredrik Mattsson was re-elected Chairman of the
Board.

• Remuneration to the members of the Board shall be SEK 520,000 in total, of
which SEK 160,000 is allocated to the Chairman of the Board and SEK 90,000 to
each Board member who are not an employee of the company.

• Establishment of nomination committee for the next annual general meeting, in
accordance with the election committee’s proposal.

• Authorization for the Board, for the time up until the next Annual General
Meeting and on one or more occasions, to take a decision on the issue of a
maximum of 2,150,000 shares in total, corresponding to just below 10 percent of
the company’s share capital.

• The proposed principles for remuneration and other conditions of employment
for the senior management were approved.

• The proposed issuance of a total of 215,000 warrants with the right to
subscribe for new shares was approved. The warrants shall be offered to
employees in the XVIVO Perfusion Group. Upon full exercise of the warrants, the
share capital increase is SEK 5,500 corresponding to a dilution of about 1
percent of the total number of shares and votes.

April 23, 2015
Gothenburg
XVIVO Perfusion AB (publ)
The Board
Queries should be addressed to:

Fredrik Mattsson, Chairman of the Board, phone 46 8-614 00 20
Christoffer Rosenblad, CFO, phone 46 31-788 21 59

The information was submitted for publication on April 23, 2015 at 5:20 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com